Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Prevents postoperative nausea and vomiting (PONV). Sold as Barhemsys. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Amisulpride (sold as Barhemsys), first approved Feb 26, 2020, with 0 new uses approved and 2 published complete response letters.
First approved: Feb 26, 2020
Applications: 1
New uses approved: 0
Complete response letters: 2
Clinical Trials
9 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
